Literature DB >> 32330514

The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.

Salma Siddiqui1, Stephen J Libertini2, Christopher A Lucas2, Alan P Lombard2, Han Bit Baek2, Rachel M Nakagawa3, Kristine S Nishida3, Thomas M Steele4, Frank U Melgoza1, Alexander D Borowsky5, Blythe P Durbin-Johnson6, LiHong Qi7, Paramita M Ghosh4, Maria Mudryj8.   

Abstract

Prostate cancer (PCa) is characterized by a unique dependence on optimal androgen receptor (AR) activity where physiological androgen concentrations induce proliferation but castrate and supraphysiological levels suppress growth. This feature has been exploited in bipolar androgen therapy (BAT) for castrate resistant malignancies. Here, we investigated the role of the tumor suppressor protein p14ARF in maintaining optimal AR activity and the function of the AR itself in regulating p14ARF levels. We used a tumor tissue array of differing stages and grades to define the relationships between these components and identified a strong positive correlation between p14ARF and AR expression. Mechanistic studies utilizing CWR22 xenograft and cell culture models revealed that a decrease in AR reduced p14ARF expression and deregulated E2F factors, which are linked to p14ARF and AR regulation. Chromatin immunoprecipitation studies identified AR binding sites upstream of p14ARF. p14ARF depletion enhanced AR-dependent PSA and TMPRSS2 transcription, hence p14ARF constrains AR activity. However, p14ARF depletion ultimately results in apoptosis. In PCa cells, AR co-ops p14ARF as part of a feedback mechanism to ensure optimal AR activity for maximal prostate cancer cell survival and proliferation.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Androgen receptor; Apoptosis; E2F; Prostate cancer; p14ARF

Mesh:

Substances:

Year:  2020        PMID: 32330514      PMCID: PMC8034238          DOI: 10.1016/j.canlet.2020.03.030

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  58 in total

1.  Androgen-mediated resistance to apoptosis.

Authors:  Ronan N T Coffey; R William G Watson; Amanda J O'Neill; Kevin Mc Eleny; John M Fitzpatrick
Journal:  Prostate       Date:  2002-12-01       Impact factor: 4.104

Review 2.  Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Authors:  Michael S Cookson; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine Tangen; J Brantley Thrasher; Ian Thompson
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

3.  Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.

Authors:  Benjamin A Mooso; Ruth L Vinall; Clifford G Tepper; Rosalinda M Savoy; Jean P Cheung; Sheetal Singh; Salma Siddiqui; Yu Wang; Roble G Bedolla; Anthony Martinez; Maria Mudryj; Hsing-Jien Kung; Ralph W Devere White; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

4.  Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells.

Authors:  E Diaz-Rodriguez; M García-Lavandeira; S Perez-Romero; A Senra; C Cañibano; I Palmero; M G Borrello; C Dieguez; C V Alvarez
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

5.  Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.

Authors:  J Tsihlias; W Zhang; N Bhattacharya; M Flanagan; L Klotz; J Slingerland
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

6.  ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Authors:  Delin Chen; Ning Kon; Muyang Li; Wenzhu Zhang; Jun Qin; Wei Gu
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

7.  Genomic targets of the human c-Myc protein.

Authors:  Paula C Fernandez; Scott R Frank; Luquan Wang; Marianne Schroeder; Suxing Liu; Jonathan Greene; Andrea Cocito; Bruno Amati
Journal:  Genes Dev       Date:  2003-04-14       Impact factor: 11.361

8.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

Authors:  J M Kokontis; N Hay; S Liao
Journal:  Mol Endocrinol       Date:  1998-07

Review 9.  The broken cycle: E2F dysfunction in cancer.

Authors:  Lindsey N Kent; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

Review 10.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Authors:  Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

View more
  2 in total

1.  MiR-942-3p as a Potential Prognostic Marker of Gastric Cancer Associated with AR and MAPK/ERK Signaling Pathway.

Authors:  Wenjia Liu; Nanjiao Ying; Xin Rao; Xiaodong Chen
Journal:  Curr Issues Mol Biol       Date:  2022-08-24       Impact factor: 2.976

2.  FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer.

Authors:  Yingchen Zhou; Longhua Ou; Jinming Xu; Haichao Yuan; Junhua Luo; Bentao Shi; Xianxin Li; Shangqi Yang; Yan Wang
Journal:  Cell Death Dis       Date:  2021-07-02       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.